Subscribe for the newsletter
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
MorphoSys AG
Sort By
Newest First
Sign in
1 / 1
1 / 1
MorphoSys Gets Milestone Payment from GSK for Otilimab
David Alvaro, Ph.D.
Pharma's Almanac
PA2346
Jul 22, 2019
Endpoints
MorphoSys AG: Primary Endpoint of L-MIND, a Combination Study of Tafasitamab (MOR208) and Lenalidomide, Has Been Met, Confirming Previously Published Activity
MorphoSys
PR-M05-19-NI-065
May 22, 2019
